TORONTO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- (TSX: CLSA) – As a result of strong net asset value (“NAV”) growth since the launch of Brompton Split Corp. Class A Share ETF (the “ETF”), Brompton Funds (“Brompton”) is pleased to announce an increase in the monthly distribution to $0.13 per unit for record dates from October to December 2025. This new distribution amount represents a 13% annualized increase from third quarter distributions. Since inception the NAV has grown from $10.00 per unit to $12.95 per unit ...

TORONTO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- (TSX: CLSA) – As a result of strong net asset value (“NAV”) growth since the launch of Brompton Split Corp. Class A Share ETF (the “ETF”), Brompton Funds (“Brompton”) is pleased to announce an increase in the monthly distribution to $0.13 per unit for record dates from October to December 2025. This new distribution amount represents a 13% annualized increase from third quarter distributions. Since inception the NAV has grown from $10.00 per unit to $12.95 per unit ...

TORONTO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- (TSX: BBBB, BBBB.U) Brompton Wellington Square Investment Grade CLO ETF announces distributions payable on November 14, 2025 to unitholders of record at the close of business on October 31, 2025 as follows: TickerAmount Per UnitBBBBCdn$0.09BBBB.UUS$0.09 Distributions have been adjusted to cover the first partial monthly period from the listing of the units on October 6, 2025 to October 31, 2025. About Brompton FundsFounded in 2000, Brompton is an experienced invest ...

TUCSON, Ariz., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first U.S. and Canadian commercially-approved total artificial heart, today announced that it is not aware of any undisclosed material change in the Company’s operations or financial condition, that would account for the recent volatility in its stock price. The Company remains focused on executing its strategic and operational ...

ROCKVILLE, Md., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, announced today that the Company had become aware of unusual trading activity in its common stock on the NYSE American (the “NYSE”) on October 24, 2025. The Company is issuing this press release pursuant to Section 401(d) of the NYSE Company Guide. The C ...

Core Viewpoint - Amaroq Ltd. has received a TR-1 notification from JLE Group regarding recent share transactions, indicating a change in voting rights ownership [2][3]. Group 1: Shareholder Notification - JLE Group has crossed a voting rights threshold of 2.91% in Amaroq Ltd., with a total of 13,222,545 voting rights held as of October 23, 2025 [3][4]. - The previous notification indicated a higher voting rights percentage of 4.01%, with 18,222,545 voting rights [4]. Group 2: Block Listing Return - Amaroq Ltd. has a balance of 9,160,981 unallotted securities under its Stock Option Plan as of October 23, 2025 [6][7]. - No securities were issued or allotted under the scheme during the reporting period [7]. Group 3: Company Overview - Amaroq Ltd. focuses on the exploration and development of gold and strategic metal properties in South Greenland, with its principal asset being a 100% interest in the Nalunaq Gold mine [9][10]. - The company also has advanced exploration projects in the Stendalen and Sava Copper Belt, targeting strategic metals such as Copper, Nickel, and Rare Earths [9].

CALGARY, Alberta, Oct. 24, 2025 (GLOBE NEWSWIRE) -- At the request of CIRO, Cielo Waste Solutions Corp. (TSXV: CMC; OTCQB: CWSFF) (“Cielo” or the “Company”) wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity. ABOUT CIELO Cielo Waste Solutions Corp. is a publicly traded company focused on transforming waste materials into high-value products. Cielo seeks to address global waste challenges ...

Clermont-Ferrand (France), October 24, 2025 (08:00 pm CEST). CARBIOS (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastics and textiles, informs its shareholders and the financial community that it has made available its Interim report for the first half of 2025. This 2025 Interim report is available in English and can be downloaded from: The Company's website at www.carbios.com under the “Investors / Regulated ...

PASCAGOULA, Miss., Oct. 24, 2025 (GLOBE NEWSWIRE) -- HII’s (NYSE: HII) Ingalls Shipbuilding division successfully completed the second builder’s sea trials for guided missile destroyer Ted Stevens (DDG 128), building on the success of the initial trials conducted at the end of September. The Arleigh Burke-class (DDG 51) destroyer spent multiple days in the Gulf of America testing the ship’s main propulsion, combat systems and other critical systems in preparation for the future acceptance trials. “The Ingal ...

Core Insights - Syndax Pharmaceuticals has received FDA approval for Revuforj (revumenib) as the first and only therapy for both relapsed or refractory (R/R) acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation, marking a significant advancement in treatment options for these aggressive blood cancers [2][3][4] Company Developments - Revuforj is now approved for use in adult and pediatric patients aged one year and older who have no satisfactory alternative treatment options, expanding its indication from a previous approval for R/R acute leukemia with a KMT2A translocation [2][11] - The approval is based on data from the Phase 2 portion of the AUGMENT-101 trial, which demonstrated a complete remission (CR) plus CR with partial hematological recovery (CRh) rate of 23% among patients with R/R NPM1 mutated AML [3][4] - The median time to CR or CRh response was reported at 2.8 months, with a median duration of 4.5 months [3] Industry Impact - The inclusion of Revuforj in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines as a category 2A recommended treatment option for R/R NPM1 mutated AML and R/R acute leukemia with a KMT2A rearrangement underscores its significance in the oncology landscape [5][6] - The approval of Revuforj is expected to set a new standard of care for patients with these difficult-to-treat blood cancers, as highlighted by experts in the field [4][5] - The company is committed to supporting patient access through its SyndAccess program, which provides personalized support and financial assistance for eligible patients [8]